A Phase One Trail of Gemcitavine and Paclitaxel (GEMTAX) Plus Low Dose Radiation in Patients with Recurrent Head and Neck Cancer

Grants and Contracts Details

StatusFinished
Effective start/end date11/1/0510/31/09

Funding

  • Eli Lilly and Company: $39,133.00